Paris-based Aqemia, which aims to scale drug discovery using quantum physics algorithms and AI, raised a €30M Series A led by Eurazeo and Bpifrance
Patricia Allen / EU-Startups :
Context & Ripple Effects
This 2022 round put Aqemia on the map as one of the first bets pairing quantum-physics algorithms with AI-driven drug discovery, and it aged into a repeatable playbook: the company went on to raise another €30M in January 2024 and then a $38M round led by Cathay Innovation by December 2024.
The round also slots into a wider Paris quantum build-out that Bpifrance keeps anchoring — the same backer appears in Alice&Bob's fault-tolerant qubit push, PASQAL's €100M neutral-atom Series B, and later Quobly's silicon-qubit raise — making Aqemia the application-layer piece of a hardware-heavy cluster.
First-order effects
- Eurazeo and Bpifrance take early positions in Aqemia's physics-based molecular simulation platform, giving the startup runway to scale its drug-discovery engine beyond what seed funding supported.
Second-order effects
- Bpifrance's presence across Aqemia, Alice&Bob, PASQAL, and Quobly turns the French state bank into the connective tissue of a Paris quantum stack, lowering the risk premium for private co-investors like Eurazeo.
Third-order effects
- If the pattern holds, Europe's quantum sector consolidates around national champion ecosystems rather than single companies — hardware makers, application startups, and a state financier moving as one bloc against US players like SandboxAQ.
The trend: Quantum computing capital in Europe is clustering in Paris around a state-backed stack that funds hardware and AI-application layers together.